Treatment of hypertension and other cardiovascular risk factors in patients with metabolic syndrome.
Metabolic syndrome (MetS), a concurrence of hypertension, abdominal obesity, impaired fasting glucose, and dyslipidemia, has been shown to be a risk factor for cardiovascular disease. Insulin resistance has been thought to be one of the pathophysiologies of the syndrome. Reduction of the underlying causes of MetS, such as obesity, physical inactivity, and atherogenic diet, is first-line therapy. Treatment of hypertension and other cardiometabolic risk factors of MetS is also required. This article reviews the treatment of the metabolic syndrome with a focus on the importance of lifestyle changes and treatment of hypertension.
Suzuki
Takeki
T
Division of Cardiology, Department of Medicine, University of Vermont College of Medicine, 111 Colchester Avenue, Burlington, VT 05403, USA.
Homma
Shunichi
S
D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001794:Blood Pressure; D002318:Cardiovascular Diseases / Q000209:etiology / Q000628:therapy; D005081:Exercise Therapy / Q000379:methods*; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000628:therapy*; D024821:Metabolic Syndrome / Q000150:complications*; D018570:Risk Assessment; D016896:Treatment Outcome
D000959:Antihypertensive Agents